Abstract Purpose: Nanotheranostic platforms, i.e., the combination of both therapeutic and diagnostic agents on a single platform, are emerging as an interesting tool for the personalized cancer medicine. Therefore, the aim of this work was to evaluate the in vivo properties of a Tc-99m-labeled nanostructured lipid carrier (NLC) formulation, co-loaded with doxorubicin (DOX) and docosahexaenoic acid (DHA), for theranostic applications. Procedures: NLC-DHA-DOX were prepared busing the hot melting homogenization method using an emulsification-ultrasound and were radiolabeled with Tc-99m. Biodistribution studies, scintigraphic images, and antitumor activity were performed in 4T1 tumor-bearing mice. Results: NCL was successfully radiolabeled with Tc-99m. Blood clearance showed a relatively long half-life, with blood levels decaying in a biphasic manner (T 1/2 α = 38.7 min; T 1/2 β = 516.5 min). The biodistribution profile and scintigraphic images showed higher tumor uptake compared to contralateral muscle in all time-points investigated. Antitumor activity studies showed a substantial tumor growth inhibition ratio for NLC-DHA-DOX formulation. In addition, the formulation showed more favorable toxicity profiles when compared to equivalent doses of free administered drugs, being able to reduce heart and liver damage.
Introduction
Cancer is a major health issue worldwide. In 2012, there were 14.1 million new cases and 8.6 million people died due of cancer [1] . Breast cancer is the most common type of tumor among women, representing about 20 % of the new cases reported every year. Doxorubicin (DOX) is an anthracycline with a broadspectrum of anticancer activity, and is widely used in cancer therapy. However, DOX has low Btherapeutic index,m ainly due to myelosuppression and cardiotoxicity [2, 3] , limiting its use. Moreover, its low tumor penetration and limited distribution within solid tumors are the main causes of treatment failures [4] [5] [6] . The use of anthracycline-based combination chemotherapy regimens has shown improvements in activity compared to a single drug. In clinics, doxorubicin is already used combined with cyclophosphamide, cisplatin and fluorouracil. However, despite the greater activity, these regimens are also more toxic than single-drug approaches [2, 7] .
Among dual-drug strategies, the combination of docosahexaenoic acid (DHA) and doxorubicin has been described as an alternative to improve antitumor efficacy compared to doxorubicin alone [8] [9] [10] . DHA is a long-chain (C 22 ) polyunsaturated fatty acid (Omega 3) that enhances oxidative stress and subsequent lipid peroxidation of tumor cells [11] . Previous studies have reported the effect of DHA in enhancing antitumor activity of doxorubicin in rodents [9, 12] . However, variable drug administration schedules have complicated management of the pharmacokinetic and pharmacodynamic profiles, and achieving uniform temporal and spatial co-delivery remains challenging. Thus, the combination of drugs co-delivered in a single drug delivery system has emerged as an attractive alternative [13] . Furthermore, these systems are capable of raising the therapeutic index, reducing toxicity, and thereby increasing the effectiveness of the drug [14] .
Among the drug delivery systems, nanostructured lipid carrier (NLC) has emerged as an exquisite strategy due to their advantages and benefits such as easy translation to large-scale production, absence of organic solvents in its composition, and relatively low toxicity. In addition, more synchronized, controlled pharmacokinetics of the drugs and improved drug bioavailability can be achieved [15, 16] .
Theranostic platforms are emerging as interesting tools in the clinical setting. These systems are the combination of both therapeutic and diagnostic agents on a single platform [17] , in other words, by using theranostic approaches it is possible to diagnosis, treat and monitoring the efficacy of therapeutic regimens [18] . Recent advances in nanomedicine and imaging modalities enable the design of nanotheranostic agents. It is well known that nanoparticulate systems might prolong blood circulation leading to high accumulation in tumor tissue, with the ability to co-deliver therapeutic and imaging functions [19] [20] [21] . For theranostic applications, several imaging modalities are possible. Tc-99m is widely used for SPECT images in clinics, due to its suitable physical and chemical characteristics, large availability in nuclear medicine laboratories, and low isotope cost [22, 23] .
Recently, our research group demonstrated the promising cytotoxic effect of NLC loaded with doxorubicin and DHA in spheroid tumor models, when compared to both free and liposomal doxorubicin [23] . The aim of this work was to evaluate the in vivo properties of this NLC formulation for theranostic applications. To achieve this purpose, the NLC was radiolabeled with Tc-99m for scintigraphic images and biodistribution studies in tumor-bearing mice. Furthermore, antitumor activity of free and encapsulated DOX was evaluated against 4T1 breast cancer murine cells in BALB/ c mice.
Materials and Methods

Material
A description of the material, animals and cells used in this study is detailed in Electronic supplementary material (ESM).
Preparation of NLC
NLC were prepared by the hot melting homogenization method using an emulsification-ultrasound. The composition of NLC was previously described by Mussi et al. [23, 24] and more details are shown in ESM.
Characterization of NLC
The mean particle diameter and polydispersity index (PDI) were measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS90 (Malvern Instruments, UK). Zeta potential measurements were carried out by DLS associated with electrophoretic mobility, at a fixed angle of 90°and 25°C. The encapsulation efficiency (EE) of doxorubicin into NLC was determined by ultrafiltration method using passivated centrifugal devices (Amicon® Ultra -0.5 ml 100 k; Millipore, USA), as previously described [23, 24] .
Radiolabeling of NLC-DHA-DOX
One milligram of SnCl 2 ·2H 2 O in an acid solution (HCl 0.25 M) was added to a sealed vial containing 1.0 ml of the NLC suspension. The pH was adjusted to 7. Then, vacuum was applied to the vial and an aliquot of 0.1 ml of Na[
99m Tc]O 4 (37 MBq) was added to the mixture reaction. The solution was stirred by vortexing for 2 min and kept at room temperature (r.t.) for 10 min.
Radiolabeling of DOX
Doxorubicin was labeled with Tc-99m as previously described by Fernandes et al. [25] . 
Characterization of [
99m Tc]NLC-DHA-DOX
The radiolabeled complex was characterized as the mean diameter, PDI, zeta potential and EE, as previous described.
In Vitro Stability
Tests in saline 0.9 % (w/v) and in mouse plasma were performed to evaluate the stability of [ Tc]NLC-DHA-DOX complexes were administrated to each mouse (n = 6 for each complex) through the tail vein, and blood samples (∼ 20 μl each) were collected, from the tail vein, at pre-determined times. Each sample was weighted, and the radioactivity was measured with an automatic scintillation counter.
Tumor Cell Inoculation
Aliquots (100 μl) of 2.5 × 10 6 4T1 cells were injected subcutaneously into the right thigh of female BALB/c mice (18-22 g ). Tumor cells were allowed to grow in vivo for 7 days, leading to tumors with a diameter of no more than 10 mm. Breast tumor-bearing BALB/c mice were used for biodistribution studies, scintigraphic images and in vivo antitumor activity.
Scintigraphic Images
Aliquots (100 μl) of 18 MBq of [ 99m Tc]DOX or [ 99m Tc]NLC-DHA-DOX were injected intravenously into tumor-bearing BALB/c mice (n = 6). Anesthetized mice were horizontally placed under a gamma camera (Mediso, Budapest, Hungary) coupled with a low-energy highresolution collimator. Images were acquired at 1, 4, and 8 and 24 h after injection using a 256 × 256 × 16 matrix size, with a 20 % energy window set at 140 keV for a period of 300 s each.
Biodistribution Studies
Aliquots (100 μl) of 3.7 MBq of [ 99m Tc]DOX or [ 99m Tc]NLC-DHA-DOX were injected intravenously into tumor-bearing BALB/c mice (n = 6). At 1, 4, and 8 and 24 h after injection, mice were anesthetized with a mixture of xylazine (15 mg/kg) and ketamine (80 mg/kg). Liver, spleen, kidneys, stomach, heart, lungs, muscle, thyroid, intestine, and tumor were removed, and placed in pre-weighed plastic test tubes. The radioactivity was measured using an automatic scintillation counter. Results were expressed as the percentage of injected dose per gram of tissue (%ID/g).
In Vivo Antitumor Activity
On the 7th day after 4T1 cell inoculation, once the tumor volume reached 100 mm 3 , the mice were randomly assigned to four groups (n = 6 for each group), named group 1: blank-NLC (control group); group 2: free DOX; group 3: NLC-DOX; and group 4: NLC-DHA-DOX. For all treatments the dose of DOX was 4 mg/kg/day, in a total of 4 administrations, every 2 days, injected by the tail vein. Throughout the study, body weight and tumor volumes (measured with caliper) were obtained every 2 days. Ten days after the beginning of the treatment (D10), mice were euthanized and the tumors, heart, liver, spleen, lungs, and kidneys were collected for histology. Tumor volumes, relative tumor volume (RTV) and inhibition ratio (IR) were calculated (ESM). 
Tumor Histology
On D10, after mice euthanize, tumors were collected and washed with NaCl 0.9 % (w/v) solution and set in 10 % (v/v) buffered formalin for further analyses. More details see in ESM.
Toxicity Evaluation
The body weight of the mice was monitored at D0, D2, D4, D6, D8, and D10 after application, and their body weight variation was expressed as the difference between the body weight at D10 and the initial body weight. In addition, the kidneys, heart, lungs, liver, and spleen were also removed for histological analysis (ESM). A scheme of our experimental procedure is resumed in Fig. 1 .
Statistical Analysis
Statistical analyses were performed using GraphPad PRISM, version 5.00 software (GraphPad Software Inc., La Jolla, CA, USA). The difference among experimental groups was tested using the one-way analysis of variance (ANOVA), followed by Tukey's test. Student's t test was performed to compare data of the physicochemical characteristics of NLC and blood clearance. The regression model estimates were used at time intervals for tumor growth investigations. Differences were considered statistically significant when P values were G 0.05.
Results
Radiolabeling of NLC-DHA-DOX, Characterization and In Vitro Stability
Radiochemical purity of [ 99m Tc]DOX reaching values of 98.6 ± 0.4 % (n = 5). This finding is in agreement with purity reported by our group [25] , in which DOX was radiolabeled with high efficiency and high stability.
For [ 99m Tc]NLC-DHA-DOX, radiochemical purity was 95.3 ± 0.9 % (n = 5), and these results were highly reproducible during the experiments. The NLC and the radiolabeled complex were characterized according to their mean particle diameter, PDI, zeta potential and EE, and the results are shown in Table 1 .
The average size of NLC was 64.4 ± 3.6 nm, and PDI was lower than 0.3 (0.176 ± 0.01), which indicates homogeneity. NLC exhibited a negative zeta potential (− 31.6 ± 1.4 mV), which can be attributed to the presence of ionized oleic acid in the formulation. The high value of EE (96.9 ± 0.7 %) is also due to the oleic acid, a lipophilic anion that forms an ion pair with doxorubicin, increasing their affinity for the lipid matrix [23] . After radiolabeling, it is possible to observe a significant increase in mean particle diameter (72.5 ± 2.6 nm), and a significant reduce of PDI (0.139 ± 0.006) and zeta potential (− 21.7 ± 2.2 mV).
[ 99m Tc]NLC-DHA-DOX showed an excellent stability, even over long periods of time (9 85 % up to 24 h after radiolabeling), was observed, which allows further in vivo studies The radiochemical stability curve for the complex is demonstrated in ESM Fig. S1 . High uptake was observed in organs from mononuclear phagocyte system (MPS), such as the liver and spleen. In addition, no significant uptake was observed in other organs, mainly the stomach and thyroid, which corroborates the in vitro stability data, since the stomach and thyroid showed low uptake in all time frames. It is well known that free technetium are, preferentially, taken up by these organs [26] . Regarding the tumor uptake (arrows on Fig. 2) , it could be observed higher uptake compared to non-targeted tissues, such as the muscle, in all investigated time points, especially in the longest investigated point. These data are similar to those obtained by biodistribution studies (Fig. 3) . [ Fig. 3a, b , respectively. As previously described [25] , [
Blood Clearance
99m Tc]DOX shows a dualelimination pathway (renal and hepatobiliary), which clearly observed in Fig. 3b . In addition, there was higher tumor uptake compared with control tissue, in all time-points investigated.
Target-to-Non-target Ratios
Target-to-non-target ratios were obtained from biodistribution and scintigraphic images (Fig. 4) 
In Vivo Antitumor Activity
The antitumor activity of NLC-DHA-DOX was evaluated in 4T1 tumor-bearing BALB/c mice. As shown in Fig. 5 , the tumor growth was significantly lower after NLC-DOX or NLC-DHA-DOX treatments compared to blank-NLC and free DOX (p G 0.05). In addition, NLC-DHA-DOX significantly inhibited 4T1 growth compared to NLC-DOX treatment (p G 0.05).
Regression analysis was performed to detect the changes in the growth delay after treatment within the different groups. The best-fit model for each group, together with their respective determination coefficients, is shown in Table 3 . There was significant statistical difference between the free DOX and NLC-DOX, since they fit on different mathematical models. For the NLC-DHA-DOX treatment group, the tumor volume was significantly suppressed compared with the other groups with no tumor volume increment throughout the experiment, suggesting that DHA plays a substantial role in the antitumor effect. As a result, any mathematical model fits to this group as indicated in Table 3 . In addition, statistical differences were observed after the D4 by analyzing each time point individually.
Relative tumor volume (RTV) and tumor growth inhibition ratio (IR) data are shown in Table 4 and corroborate with the regression analysis findings. NLC-DHA-DOX treatment group was able to inhibit tumor growth by over 90 %; hence, RTV remained almost constant over time. Nevertheless, free doxorubicin and NLC-DOX were able to inhibit tumor growth in only 56 and 68 %, respectively. Tumor Histology Histological sections of tumor tissue were evaluated after different treatments. 4T1 tumors are characterized by epithelial cells with pleomorphism, evident nucleolus and mitosis figures [27] , which were observed in all groups. Additionally, for the treated groups, it is possible to observe necrosis areas, characterized by pyknotic nuclei and eosinophilic regions. Interestingly, free DOX group showed less intense necrosis area, indicating that NLC formulations were more effective than free drug. Histological sections of tumor tissue are demonstrated in ESM Fig.  S2 .
Toxicity Evaluation Body Weight
Loss of body weight is an important toxicological parameter of antitumor therapy that may help to predict side effects from drugs. In this study, mice weight changes after treatments are illustrated in Fig. 6 . Animals from the control group showed a positive weight variation after treatment protocol. For the treated groups, animals which received free DOX showed a severe weight loss, reaching a maximum loss on D8 of 25 % of body weight, which led to the animals' death. The animals treated with the NLC formulations showed a slight body weight loss (under 10 %), with no significant difference between them. These data suggest that the treatment with the encapsulated drug was able to alleviate the inherent toxic effects of the free drug.
Histological Analysis
The kidneys, heart, lungs, liver, and spleen were collected from animals for histological analysis. No histological changes were observed for the lungs, kidneys, and spleen, for all groups (data not shown). All evaluated groups showed preserved tissues with their typical architecture.
For all the animals treated with free DOX, it could be observed multifocal areas of hydropic degeneration in liver, with vacuolized tissue, and necrotic areas. For NLC formulations, a protective effect in the liver tissue was observed since only 30 % (2/6) of the mice showed points of hydropic degeneration. Important to mention that the livers from animals treated with NLC formulations did not show any necrotic area, indicating the capability of this nanocarrier in effectively diminish the toxic effect of doxorubicin. Liver histological sections are demonstrated in ESM Fig. S3 .
It is well known that anthracyclines, including DOX, are potentially cardiotoxic often limiting their use in the clinics. For this reason, the hearts were also collected and evaluated after the different treatments employed. As observed for all the other organs evaluated, no histological change was observed for the control group. However, for all treated groups, there were focal areas of hyaline degeneration, characterized by thick and strongly eosinophilic cardiac fibers. Similar to the results described in the liver analysis, the extent and the frequency of the tissue damage were different for free and encapsulated drug. Meanwhile, the hearts from free DOX group showed multifocal areas of hyaline degeneration in 100 % of the animals, while for the NLC-DHA-DOX group this change was observed in only 30 % (2/6) of the animals. Once again, indicating the protective effect of the formulation over the free drug. Heart histological sections are demonstrated in ESM Fig. S3 .
Discussion
Combination therapies have gained much attention as an alternative to improve cancer treatment [2, 7] . In this scenario, improved antitumor efficacy have described by the combination of doxorubicin and DHA [9] [10] [11] [12] [13] . Nanocarriers have become a tool to overcome chemotherapy limitations, such as drug resistance, bioavailability, adverse effects, besides provides a uniform temporal and spatial codelivery of the two encapsulated drugs [13] [14] [15] [16] . The [ 99m Tc]NLC-DHA-DOX was characterized as mean diameter, PDI, zeta potential and EE (Table 1) . The significant increase in mean diameter and the reduction of the zeta potential are, probably, due to an incorporation of Tc-99m, which is a positive metal. The significant PDI decrease might be a consequence of the filtration step, which removes particle populations larger than 200 nm along with radiocolloids. Importantly, although a slight increase in the particle size was evidenced after radiolabeling procedure, the final mean diameter and PDI remain under the envisioned size range for in vivo applications [28] [29] [30] . In addition, upon the labeling protocol used it was possible to efficiently radiolabeled NLC with minimum effect on their physicalchemical features. Therefore, this technique could be a possibility for labeling other particles for bioimaging approaches without using a chelating agent to stabilize the metal complex.
[ 99m Tc]NLC-DHA-DOX showed excellent radiochemical stability over time (Fig. S1 ). This data is in agreement with previous studies, which have related high stability for SLN [31] radiolabeled with Tc-99m. The choice in labeling the surface of NLC is due to the fact that doxorubicin, as itself, is a hydrophilic drug not being incorporated into the hydrophobic core of NLC. As proposed by our group, an ion-pair between oleic acid and DOX must be prepared to encapsulate efficiently the drug. However, the amino group of the doxorubicin is responsible for both complexation with technetium, and formation of ion-pair with oleic acid [23, 25] . Therefore, the encapsulation of [
99m Tc]DOX complex into NLC was not possible. It is worthy to mention that previous release studies have demonstrated a controlled release of doxorubicin; therefore, the drug is stable into NLC even after long periods [23, 24] . These data indicate that in vivo assay carried out with [ 99m Tc]NLC-DHA-DOX will reflect the fate of the encapsulated drug.
The use of a radiolabeled nanoparticles carrying antitumor drug might be an alternative for the future of the personalized medicine, taking advantage from the high sensitivity of nuclear medicine imaging associate with potentialities of nanomedicine for antitumor therapies [17] [18] [19] [20] .
[ 99m Tc]NLC-DHA-DOX exhibited longer blood circulation time compared to the free drug ( Table 2 ). The small particle size of NLC (~70 nm), along with the presence of hydrophilic surfactant (Tween 80), might contribute to the prolonged circulation time. Polyethylene glycol chains (PEG) in the Tween 80 may provide Bstealth^properties to nanoparticles [32, 33] .
The target-to-non target ratios (Fig. 3) 99m Tc]NLC-DHA-DOX allows that nanoparticles pass though the tumor area more times than the free drug favoring their accumulation by the enhanced permeability and retention effect (EPR effect). This effect is a well-established phenomenon in which the endothelial lining of the blood vessel wall of tumors becomes more permeable than in the normal state. As a result, in such areas, particles ranging from 10 to 500 nm in size can leave the vascular bed and accumulate inside the interstitial space. Moreover, the compromised lymphatic filtration impair a proper drainage resulting in their accumulation. Unlike these nanoparticles, low-molecular-weight pharmaceutical agents, like doxorubicin, are not retained in tumors because they freely diffuse from tumors and return to the circulation [28, 29, [34] [35] [36] [37] [38] .
Tumor volume data corroborate the findings in the biodistribution and scintigraphic images, where the higher tumor accumulation of NLC-DHA-DOX leads to a better antitumor activity. The treatment groups that received doxorubicin-loaded nanoparticles (Fig. 4, Table 4 ) had a slower tumor growth, and increased necrosis areas in the histological sections (Fig. S2) , showing that nanocarriers are an interesting approach to delivery drugs to the tumor site.
There are several studies reporting the advantages in using different types of nanoparticles loaded with doxorubicin for the antitumor activity [39] [40] [41] .
With regard to the NLC-DHA-DOX, the small particle size, along with the EPR effect and the controlled release of doxorubicin from the particle [23] , contributes to the increase of antitumor effectiveness. Besides that, it is possible to observe the substantial contribution of DHA in the antitumor activity. DHA might contribute to enhance anticancer therapy by different mechanisms, such as improving sensitization of cells to anticancer drugs, favoring uptake of chemotherapeutic agents, overcoming drug resistance, and reducing inherent drug-associated side effects [10] . Furthermore, as DHA is a highly polyunsaturated fatty acid, cell membrane might be more susceptible to lipid peroxidation leading to membrane damage [42] . Results obtained by in vivo distribution and antitumor activity accredit NLC-DHA-DOX, in combination with technetium99m, a potential theranostic tool for breast tumor therapy.
The search for new therapeutic alternatives in cancer treatment aims to develop potentially effective formulations, but above all with low toxicity. Concerning to the weight variation, it is possible to suggest the safety of the blank formulation, once the group that received blank-NLC was the only group that gained weight over time. These data were expected, since only biocompatible lipids and standard surfactants for parenteral administration, such as Tween 80, were used [15, 43] . The histological analysis also confirms the reduction of toxicity compared to free drug. It is already known that nanocarriers are extensively uptaken by MPS, leading to higher uptake in the liver and spleen [30, 44] . Liver evaluation shows that, despite the presence of degeneration areas in the tissue of animals treated with the formulations, the encapsulation into nanocarrier offers a protective effect, since the extent and frequency of areas of degeneration were significantly reduced after encapsulation. Additionally, heart tissue histological evaluation also indicated a potential cardio-protective effect for NLC-DHA-DOX group and these findings are in agreement with previous studies using nanocarriers loaded with doxorubicin [45, 46] .
Conclusions
In summary, from labeling NLC-DHA-DOX surface with technetium-99m, it was possible to evaluate their biodistribution profile and to confirm the preferential accumulation in the tumor. The longer circulation time contribute to the tumor accumulation in a high payload leading to a greater antitumor effectiveness. Furthermore, data showed the antitumor activity increment by using DHA. In addition, NLC-DHA-DOX was able to reduce the toxicity compared to the free drug. Therefore, NLC-DHA-DOX formulation has shown great potential for using in breast cancer treatment and diagnosis/monitoring, leading to a new possibility of a theranostic platform.
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